Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies

详细信息    查看全文

• 作者：Michael D. Miedema ; MD ; MPH^a ; ^{mdm307@mail.harvard.edu" class="auth_mail" title="E-mail the corresponding author} ; Salim S. Virani ; MD ; PhD^b
• 刊名：The American Journal of Cardiology
• 出版年：2016
• 出版时间：15 September 2016
• 年：2016
• 卷：118
• 期：6_supp_S
• 页码：13A-18A
• 全文大小：171 K

文摘

Despite significant progress in pharmacologic treatment aimed at lowering low-density lipoprotein cholesterol to reduce cardiovascular disease risk, a number of patient groups that often prove difficult to treat remain. Patients with familial hypercholesterolemia may go undiagnosed and untreated or, despite treatment, have persistently elevated lipid levels that confer a high cardiovascular disease risk. Although the true prevalence is unknown, statin intolerance is a common clinical presentation that is difficult to assess and frequently leads to suboptimal lipid treatment. Additionally, some patients may not achieve the expected response to guideline-based therapy. For all 3 groups, a standardized approach offers the best chance for effective diagnosis and optimal treatment.